HLS Therapeutics Inc (FRA:74D)
€ 2.38 0.08 (3.48%) Market Cap: 78.06 Mil Enterprise Value: 126.68 Mil PE Ratio: 0 PB Ratio: 1.08 GF Score: 66/100

Q2 2020 HLS Therapeutics Inc Earnings Call Transcript

Aug 06, 2020 / 12:30PM GMT
Operator

Good morning, and welcome to the Q2 2020 Financial Results Conference Call for HLS Therapeutics. On this morning's call, we have Greg Gubitz, Chief Executive Officer; Gilbert Godin, President and Chief Operating Officer; and Tim Hendrickson, Chief Financial Officer. (Operator Instructions)

Earlier this morning, HLS issued a news release announcing its financial results for the 3 and 6 months period ended June 30, 2020. This news release, along with the company's MD&A and financial statements, will be available on HLS' website and on SEDAR. Certain matters discussed in today's conference call or answers that may be given to questions could constitute a forward-looking statement. Actual results could differ materially from those anticipated. Risk factors that could affect results are detailed in the company's annual information form, which has been filed on SEDAR and can be accessed at www.sedar.com.

During this conference call, HLS will refer to adjusted EBITDA. Adjusted EBITDA does not have any standardized meaning

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot